Research progress on the relationship between changes in the bile duct microbiota and cholangiocarcinoma

doi:10.3877/cma.j.issn.1674-0793.2026.03.008

Abstract

Abstract:

Cholangiocarcinoma (CCA) is a highly malignant tumour of the biliary tract system, characterised by its aggressive nature, poor prognosis, and complex pathogenesis. In recent years, particularly with the advancements in high-throughput sequencing technology, the role of changes in the biliary tract microbiota in the occurrence, development, and diagnosis of CCA has garnered significant attention. This review examines the specific changes in the biliary tract microbiota associated with CCA, underlying the mechanisms by which alterations in the biliary tract microbiota drive the development and progression of CCA, and the potential value of biliary tract microbiota intervention in the prevention and treatment of CCA. The aim is to explore new directions for the prevention and treatment strategies of CCA.

Key words: Gastrointestinal microbiome, Bile duct neoplasms, Biliary tract microbiota, Inflammatory response, Metabolic products

Jiyue Zhang, Zhiwei Liu, Jianyong Cui, Qiangpu Chen. Research progress on the relationship between changes in the bile duct microbiota and cholangiocarcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2026, 20(03): 187-191.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2026.03.008

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2026/V20/I03/187

Figures/Tables 1

References 46

［1］	Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors[J]. Liver Int, 2019, 39(Suppl 1): 19–31.
［2］	Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma[J]. Eur J Surg Oncol, 2025, 51(2): 107064.
［3］	Rodrigues PM, Olaizola P, Paiva NA, et al. Pathogenesis of cholangiocarcinoma[J]. Ann Rev Pathol, 2021, 16: 433–463.
［4］	Lyu Z, Yu T, Zhang L, et al. Analysis of the relationship between bile duct and duodenal microbiota reveals that potential dysbacteriosis is the main cause of primary common bile duct stones[J]. Synth Syst Biotechnol, 2021, 6(4): 414–428.
［5］	Molinero N, Ruiz L, Milani C, et al. The human gallbladder microbiome is related to the physiological state and the biliary metabolic profile[J]. Microbiome, 2019, 7(1): 100.
［6］	Jin W, Xiao L, Jeong M, et al. Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity[J]. Cell, 2025, 188(9): 2336–2353.
［7］	Bai X, Duan Z, Deng J, et al. Ginsenoside Rh4 inhibits colorectal cancer via the modulation of gut microbiota-mediated bile acid metabolism[J]. J Adv Res, 2025, 72: 37–52.
［8］	Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile acid physiology[J]. Ann Hepatol, 2017, 16(Suppl. 1: s3–105.): s4-s14.
［9］	Ding L, Han G, Wang X, et al. Gallbladder microbiota in early vertebrates provides evolutionary insights into mucosal homeostasis[J]. Front Immunol, 2022, 13: 1020413.
［10］	Lehmann PV, Forsthuber T, Miller A, et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen[J]. Nature, 1992, 358(6382): 155–157.
［11］	Berg PA. Autoimmunity in primary biliary cirrhosis: An alternative view at initiation and function of anti-mitochondrial autoantibodies[J]. J Hepatol, 2009, 50(4): 827–828.
［12］	Liwinski T, Zenouzi R, John C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis[J]. Gut, 2020, 69(4): 665–672.
［13］	Lee J, Kim H, Park J. Beyond the bile: exploring the microbiome and metabolites in cholangiocarcinoma[J]. Life, 2024, 14(6): 698.
［14］	Saab M, Mestivier D, Sohrabi M, et al. Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma[J]. Plos One, 2021, 16(3): e247798.
［15］	Kaewpitoon SJ, Loyd RA, Rujirakul R, et al. Helicobacter species are possible risk factors of cholangiocarcinoma[J]. Asian Pac J Cancer Prev, 2016, 17(1): 37–44.
［16］	Park W, Lee SK, Gwack J, et al. Dysbiosis of bile microbiota in cholangiocarcinoma patients: A comparison with benign biliary diseases[J]. Int J Mol Sci, 2025, 26(4): 1577.
［17］	Li Z, Chu J, Su F, et al. Characteristics of bile microbiota in cholelithiasis, perihilar cholangiocarcinoma, distal cholangiocarcinoma, and pancreatic cancer[J]. Am J Transl Res, 2022, 14(5): 2962–2971.
［18］	桑慧, 李文洁, 周颖, 等. 胆汁酸、肠道微生物与胆管癌发生和发展关系的研究进展[J]. 中华肝脏病杂志, 2021, 29(5): 493–496.
［19］	Petrov VA, Fernández-Peralbo MA, Derks R, et al. Biliary microbiota and bile acid composition in cholelithiasis[J]. Biomed Res Int, 2020, 2020(1): 1242364.
［20］	Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J]. Nature, 2013, 499(7456): 97–101.
［21］	Ketpueak T, Thiennimitr P, Apaijai N, et al. Association of chronic opisthorchis infestation and microbiota alteration on tumorigenesis in cholangiocarcinoma[J]. Clin Transl Gastroenterol, 2020, 12(1): e292.
［22］	Petrick JL, Sahasrabuddhe VV, Chan AT, et al. NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project[J]. Cancer Prev Res, 2015, 8(12): 1156–1162.
［23］	Yang H, Li TW, Peng J, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression[J]. Gastroenterology, 2011, 141(1): 378–388.
［24］	Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis[J]. J Hepatol, 2020, 72(1): 95–103.
［25］	Selvaggi F, Lopetuso LR, Delli Pizzi A, et al. Diagnosis of cholangiocarcinoma: the new biological and technological horizons[J]. Diagnostics, 2025, 15(8): 1011.
［26］	Wu N, Bayatpour S, Hylemon PB, et al. Gut microbiome and bile acid interactions: mechanistic implications for cholangiocarcinoma development, immune resistance, and therapy[J]. Am J Pathol, 2025, 195(3): 397–408.
［27］	Gu D, Zhao X, Song J, et al. Expression and clinical significance of interleukin-6 pathway in cholangiocarcinoma[J]. Front Immunol, 2024, 15: 1374967.
［28］	Ishigami K, Nosho K, Koide H, et al. MicroRNA-31 reflects IL-6 expression in cancer tissue and is related with poor prognosis in bile duct cancer[J]. Carcinogenesis, 2018, 39(9): 1127–1134.
［29］	Degand N, Dautremer J, Pilmis B, et al. Helicobacter bilis-associated suppurative cholangitis in a patient with X-linked agammaglobulinemia[J]. J Clin Immunol, 2017, 37(7): 727–731.
［30］	Yamashita M, Adachi T, Ono S, et al. Helicobacter bilis infection induces oxidative stress in and enhances the proliferation of human cholangiocytes[J]. Helicobacter, 2022, 27(4): e12908.
［31］	Chen F, Sheng J, Li X, et al. Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression[J]. Front Immunol, 2024, 15: 1451474.
［32］	Yang L, Han P, Cui T, et al. M2 macrophage inhibits the antitumor effects of lenvatinib on intrahepatic cholangiocarcinoma[J]. Front Immunol, 2023, 14: 1251648.
［33］	Zhang Y, Chen S, Li J, et al. Immune infiltrating cells in cholangiocarcinoma may become clinical diagnostic markers: based on bioinformatics analysis[J]. World J Surg Oncol, 2021, 19(1): 59.
［34］	Liu D, Heij LR, Czigany Z, et al. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma[J]. J Exp Clin Cancer Res, 2022, 41(1): 127.
［35］	Zhang G, Li J, Li G, et al. Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions[J]. Clin Exp Med, 2024, 24(1): 193.
［36］	Poudel SK, Padmanabhan R, Dave H, et al. Microbiomic profiles of bile in patients with benign and malignant pancreaticobiliary disease[J]. Plos One, 2023, 18(4): e283021.
［37］	Wang J, Liu Q, Jin S, et al. Characterization of bile microbiota in patients with obstructive jaundice associated with biliary tract diseases[J]. Clin Transl Gastroenterol, 2025, 16(7): e841.
［38］	李丹. 胆总管结石与胆管癌患者胆道菌群对比研究[D]. 延安: 延安大学, 2021: 18.
［39］	Wang L, Zhao H, Wu F, et al. Bile-liver phenotype: exploring the microbiota landscape in bile and intratumor of cholangiocarcinoma[J]. Comput Struct Biotechnol J, 2025, 27: 1173–1186.
［40］	Grigor Eva IN, Romanova TI. Gallstone disease and microbiome[J]. Microorganisms, 2020, 8(6): 835.
［41］	Chen X, Sun S, Yan X, et al. Predictive factors and microbial spectrum for infectious complications after hepatectomy with cholangiojejunostomy in perihilar cholangiocarcinoma[J]. Surg Infect, 2020, 21(3): 275–283.
［42］	Picardo SL, Coburn B, Hansen AR. The microbiome and cancer for clinicians[J]. Crit Rev Oncol Hematol, 2019, 141: 1–12.
［43］	Riquelme E, Zhang Y, Zhang L, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes[J]. Cell, 2019, 178(4): 795–806.
［44］	Özdirik B, Müller T, Wree A, et al. The role of microbiota in primary sclerosing cholangitis and related biliary malignancies[J]. Int J Mol Sci, 2021, 22(13): 6975.
［45］	Tan N, Lubel J, Kemp W, et al. Current therapeutics in primary sclerosing cholangitis[J]. J Clin Transl Hepatol, 2023, 11(5): 1267–1281.
［46］	Qin H, Yuan B, Huang W, et al. Utilizing gut microbiota to improve hepatobiliary tumor treatments: recent advances[J]. Front Oncol, 2022, 12: 924696.

[1]	Xia Li, Shiping Li, Yi Qu. Current research status on mechanism of immune factors in occurrence and development of neonatal necrotizing enterocolitis [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2026, 22(02): 93-102.
[2]	Jihong Fei, Sijia Liu, Yunjian Liu. Research progress on the relationship between gut microbiota and primary liver cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(05): 347-350.
[3]	Sizhuo Wang, Xiaoxin Duan, Long Chen, Shengli Dong. Causal effect of gut microbiome， blood metabolites and gastric cancer： A mediated Mendelian randomization study in East Asian populations [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(03): 163-168.
[4]	Jin Wang, Yijie Zhao, Yongjie Sun, Peizhong Shang, Huaping Gu, Xiaowu Li, Guohong Jia, Jianjun Miao, Xiaoli Chen, Xue Yang. Expression and clinical significance of PKM2 and HSP90α in cholangiocarcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2026, 20(03): 239-243.
[5]	Zhengyuan Yan, Heng Zhang, Nengqi Cao, Xingchao Fang, Damin Chen. Clinical observation on the efficacy and safety of single-port plus one laparoscopic radical resection for colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(06): 615-618.
[6]	Jing Hong, Yi Gao, Guilan Liao, Xiaowei Chen, Zhiyuan Jian, Juanjuan Zhou, Zhiqiong Huang, Yu Wei, Yanting Deng. A study on the application of laparoscopic right hemicolectomy with ileocecal preservation in hepatic flexure and transverse colon tumors [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(05): 547-550.
[7]	Feiran Jia, Shuhan Si, Xiaoyu Zhang, Xiaohua Xu. Advances in the mesenchymal stem cell therapy for diabetic nephropathy [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2026, 16(02): 110-118.
[8]	Sijie Huang, Huiyong Zhang, Xiaohui Guo, Chengrun Xu. Prognostic value of systemic inflammatory response index in patients with advanced liver cancer after TACE combined with targeted immunotherapy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(03): 355-361.
[9]	Qinying Han, Lei Gao, Puyi He, Yunpeng Wang, Zhuanfang Wang, Lijuan He, Ben Liu, Bo Xu, Jike Hu, Weigao Pu, Hao Chen. Application of ERCP combined with SpyGlass endoscopic radiofrequency ablation+photodynamic therapy+biliary stenting in advanced cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 262-269.
[10]	Yani Gou, Qunbin Shen, Li Zhang, Jiajia Lu. Interaction mechanisms, challenges, and intervention strategies between helicobacter pylori eradication therapy and gut microbiota dysbiosis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(04): 359-363.
[11]	Chenlong Liu, Yilei Xiao, Xiaohui Xing, Xueyuan Li. Research progress of miRNAs in modulating inflammatory responses via the NF-κB pathway to implicate for spinal cord injury prognosis [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2026, 12(01): 52-56.
[12]	Jianbo Ma, Hao Xu, Yixiao Chen. Mechanism of human umbilical cord mesenchymal stem cell-derived exosomes on inflammatory response and neural damage after intracerebral hemorrhage [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2025, 11(05): 280-289.
[13]	Zhiwei Fu, Jintao Wu, Shutao Zhang, Bing Yue. Preoperative regular exercise can prevent and mitigate knee periprosthetic joint infection [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2026, 12(01): 15-24.
[14]	Yi Zhou, Ronghua Huang, Zhengjiang Liu. Research progress of 5-hydroxytryptamine and ferroptosis-mediated septic cardiomyopathy [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(08): 612-617.
[15]	Yu Xia, Han Liu, Rui Zhu. Research advances in cerebral small vessel disease and its associated cognitive impairment [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2025, 19(02): 155-160.

Please choose a citation manager

Content to export